US court denies Provenge supporters' appeal
This article was originally published in Scrip
Executive Summary
A US federal appeals court has declined to reinstate a patient advocacy group's lawsuit challenging the FDA's refusal to approval Dendreon's novel prostate cancer vaccine Provenge (sipuleucel-T). The court affirmed a November ruling by an Ohio federal judge, who said Care to Live's claims against three federal officials and an FDA advisory panel member who voted against recommending Provenge for approval were not ripe for adjudication because the agency has not taken final action on the BLA. In May 2007 the FDAissued a "complete response" letter to Dendreon requesting additional data to support the vaccine's efficacy. Care to Live – which represents cancer patients, families, doctors, investors and advocates – sued the agency, alleging that political infighting impacted the agency's decisions. Care to Live's website said the group will petition the Supreme Court for review.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.